

Supplemental Table 5. Associations between aging constructs and mortality in cancer survivors and controls; cancer cases diagnosed within two years of blood collection were excluded, HRS (2016-2020)

| <b>Sample A<sup>a</sup></b>   |               |                   |   |                      |
|---|---------------|-------------------|---|----------------------|
| <i>Cancer survivors (N = 845)<sup>b</sup></i>                             |               |                   |   |                      |
| Aging constructs  | No. of deaths | Total person-year | HR (95% CI) per 1 SD increase in aging constructs |                      |
|   |               |                   | Model 2 <sup>d</sup>                              | Model 2 <sup>d</sup> |
| KDM-BA-Accel (SD = 4.02 years)  | 108           | 3,379             | 1.14 (0.95, 1.36)                                 | 1.08 (0.89, 1.30)    |
| PhenoAgeAccel (SD = 7.19 years)   |               |                   | 1.47 (1.13, 1.91)                                 | 1.44 (1.07, 1.94)    |
| SA-Accel (SD = 10.33 years)   |               |                   | 0.99 (0.68, 1.43)                                 | 0.93 (0.65, 1.34)    |
| <i>Controls (N = 4,461)<sup>b</sup></i>                                   |               |                   |   |                      |
| Aging constructs  | No. of deaths | Total person-year | HR (95% CI) per 1 SD increase in aging constructs |                      |
|   |               |                   | Model 2 <sup>d</sup>                              | Model 2 <sup>d</sup> |
| KDM-BA-Accel (SD = 3.77 years)  | 242           | 18,468            | 1.39 (1.20, 1.61)                                 | 1.32 (1.10, 1.59)    |
| PhenoAgeAccel (SD = 7.09 years)   |               |                   | 1.46 (1.29, 1.66)                                 | 1.41 (1.21, 1.65)    |
| SA-Accel (SD = 10.37 years)   |               |                   | 1.24 (0.98, 1.55)                                 | 1.20 (0.98, 1.46)    |
| <b>Sample B<sup>a</sup></b>   |               |                   |   |                      |
| <i>Cancer survivors (N = 513)<sup>b</sup></i>                             |               |                   |   |                      |
| Aging constructs  | No. of deaths | Total person-year | HR (95% CI) per 1 SD increase in Aging constructs |                      |
|   |               |                   | Model 2 <sup>d</sup>                              | Model 2 <sup>d</sup> |
| HannumAccel (SD = 5.48 years)   | 88            | 2,011             | 1.23 (1.04, 1.45)                                 | 1.34 (1.13, 1.58)    |
| HorvathAccel (SD = 6.94 years)  |               |                   | 1.19 (0.95, 1.49)                                 | 1.27 (1.02, 1.58)    |
| LevineAccel (DNAmPhenoAge) (SD = 6.89 years)                              |               |                   | 1.48 (1.22, 1.80)                                 | 1.55 (1.26, 1.93)    |
| GrimAgeAccel (SD = 4.66 years)  |               |                   | 2.01 (1.55, 2.60)                                 | 2.09 (1.45, 3.00)    |
| POA (SD = 0.09 years of physiological decline per one chronological year) |               |                   | 1.30 (1.03, 1.65)                                 | 1.13 (0.82, 1.57)    |
| <i>Controls (N = 2,733)<sup>b</sup></i>                                   |               |                   |   |                      |
| Aging constructs  | No. of deaths | Total person-year | HR (95% CI) per 1 SD increase in Aging constructs |                      |
|   |               |                   | Model 1 <sup>c</sup>                              | Model 2 <sup>d</sup> |
| HannumAccel (SD = 5.11 years)   | 207           | 11,145            | 1.22 (1.03, 1.44)                                 | 1.20 (1.00, 1.44)    |
| HorvathAccel (SD = 6.23 years)  |               |                   | 1.08 (0.88, 1.32)                                 | 1.05 (0.85, 1.31)    |
| LevineAccel (SD = 6.72 years)   |               |                   | 1.15 (0.94, 1.39)                                 | 1.10 (0.89, 1.34)    |
| GrimAgeAccel (SD = 4.65 years)  |               |                   | 1.54 (1.32, 1.79)                                 | 1.42 (1.15, 1.74)    |
| POA (SD = 0.09 years of physiological decline per one chronological year) |               |                   | 1.42 (1.26, 1.62)                                 | 1.30 (1.14, 1.49)    |

<sup>a</sup>Sample A includes participants who had measures of KDM-BA, PhenoAge, and SA. Sample B includes participants who had data on ECs.

<sup>b</sup>Controls are participants without a history of cancer in 2016. Cancer survivors are participants with a history of cancer in 2016.

<sup>c</sup>Model 1 was adjusted for chronological age.

<sup>d</sup>Model 2 was adjusted for chronological age, sex, race/ethnicity, BMI, smoking status, comorbidity index, and CMV infection.